EntreMed Inc., of Rockville, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, reported financial results for the three months ended March 31, 2014.

Tagged with: entremed maryland rockville

EntreMed Inc., of Rockville, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, reported a fourth-quarter net loss of $1.3 million, or 5 cents per diluted share, versus a net loss of $360,000, or 2 cents per diluted share, for the prior-year period.

Tagged with: entremed maryland rockville

EntreMed Inc., of Rockville, a clinical-stage pharmaceutical company developing drugs for the treatment of cancer, reduced its net loss in the 2013 first-quarter, reporting a loss of $1.1 million, or 5 cents per diluted share versus a net loss of $2.5 million, or 23 cents per diluted share, for the same period last year.

Tagged with: Business earnings entremed first quarter revenue rockville

EntreMed Inc., a clinical-stage pharmaceutical company developing drugs for the treatment of cancer, announced it has received a patent from the Chinese State Intellectual Property Office for ENMD-2076, its lead drug candidate.

Tagged with: breast cancer cancer entremed medication rockville

EntreMed Inc., of Rockville, a clinical-stage pharmaceutical company developing drugs for the treatment of cancer, reported a fourth-quarter net loss of $360, 4303, or 2 cents per diluted share, versus net income of 1 million, or 6 cents per diluted share, for the prior-year period.

Tagged with: breaking news earnings entremed maryland News rockville

EntreMed Inc. of Rockville, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, reported fourth-quarter net income of $1 million, or 6 cents per diluted share, versus net income of $1.1 million, or 7 cents per diluted share, ...

Tagged with: entremed pharmaceuticals revenue

EntreMed Inc. of Rockville, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, said it narrowed its loss for the second quarter. EntreMed reported a net loss of $1.7 million, or 17 cents per share, for this year’s ...

Tagged with: earnings entremed pharmaceutical rockville